PRTA Company Profile and Key Details
Prothena Corporation plc
PRTA Stock Price Chart
Stock Price Today
Prothena Corporation plc (PRTA) stock surged +2.27%, trading at $14.43 on NASDAQ, up from the previous close of $14.11. The stock opened at $14.06, fluctuating between $13.82 and $14.77 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Company Information
| Employees | 173 |
| Beta | 0.16 |
| Sales or Revenue | $91.37M |
| 5Y Sales Change% | 70.122% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Prothena Corporation plc (NASDAQ: PRTA) stock price is $14.43 in the last trading session. During the trading session, PRTA stock reached the peak price of $14.77 while $13.82 was the lowest point it dropped to. The percentage change in PRTA stock occurred in the recent session was 2.27% while the dollar amount for the price change in PRTA stock was $0.32.
The NASDAQ listed PRTA is part of Biotechnology industry that operates in the broader Healthcare sector. Prothena Corporation plc designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Carol D. Karp
Chief Regulatory Officer
Dr. Hideki Garren M.D., Ph.D.
Chief Medical Officer
Ms. Karin L. Walker CPA, CPA
Chief Accounting Officer & Controller
Ms. Jennifer Zibuda
Director of Investor Relations & Communication
Mr. Brandon S. Smith
Chief Operating Officer
Mr. Michael J. Malecek
Chief Legal Officer & Company Sec.
Dr. Gene G. Kinney Ph.D.
Pres, Chief Executive Officer & Director
Dr. Wagner M. Zago
Chief Scientific Officer
Ms. Yvonne M. Tchrakian
Company Sec.
Mr. Tran B. Nguyen M.B.A.
Chief Financial Officer & Chief Strategy Officer
PRTA's closing price is 23.33% higher than its 52-week low of $11.70 where as its distance from 52-week high of $34.17 is -57.77%.
Number of PRTA employees currently stands at 173.
Official Website of PRTA is: https://www.prothena.com
PRTA could be contacted at phone 353 123 62500 and can also be accessed through its website. PRTA operates from 77 Sir John Rogerson’s Quay, Dublin, 2, Ireland.
PRTA stock volume for the day was 323.93K shares. The average number of PRTA shares traded daily for last 3 months was 568.17K.
The market value of PRTA currently stands at $776.46M with its latest stock price at $14.43 and 53.81M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com